Pharmaceutical therapy-related quality of life in Thai depressive outpatients

Authors

  • Phantipa Sakthong, Ph.D. Faculty of Pharmaceutical Sciences, Chulalongkorn University
  • Rawikarn Ralukruedej, M.S. Uthai Thani hospital

Keywords:

antidepressant, depression, quality of life

Abstract

Objectives: To evaluate pharmaceutical therapy-related quality of life in depressive outpatients and to assess its relationships with patients’ demographic and clinical characteristics.

Methods: One hundred and thirty-eight outpatients with depression were purposively selected at Srithanya hospital between April 2018 and March 2019. Health-related quality of life with respect to medication therapy was assessed using the patient-reported outcomes measure of pharmaceutical therapy (PROMPT). The PROMPT consists of 16 items and eight domains: medicine and disease information, satisfaction of medicine effectiveness, impacts of medicines and side effects, psychological impacts of medication use, convenience, availability and accessibility, therapeutic relationships with healthcare providers, and overall quality of life. Multivariate linear regressions were used to assess the relationships between eight PROMPT domain scores and patient’s demographic and clinical characteristics.

Results: Mean scores of eight PROMPT domains ranged between 58 and 80 (moderate-to-excellent level of pharmaceutical therapy-related quality of life). The domains with the lowest and highest scores were medication and disease information and availability/accessibility, respectively. Young age, female, lower education, having financial burden, more number of medications, having side effects of medication, and perceived poor disease control were significantly correlated with lower PROMPT domain scores.

Conclusion: Healthcare providers should provide adequate drug and disease information to patients and pay more attention to correlates of pharmaceutical therapy-related quality of life, including financial burden, the number of medications per day, side effects of medication and perceived level of disease control.

Downloads

Download data is not yet available.

References

World Health Organization. Depression and other common mental disorders: global health estimates. Geneva; 2017.

พันธุ์นภา กิตติรัตนไพบูลย์, นพพร ตันติรังสี, วรวรรณ จุฑา, อธิบ ตันอารีย์, ปทานนท์ ขวัญสนิท, สาวิตรี อัษณางค์กรชัย, และคณะ. ความชุกของโรคจิตเวชและปัญหาสุขภาพจิต : การสำรวจระบาดวิทยาสุขภาพจิตของคนไทยระดับชาติ ปี พ.ศ. 2556 [Prevalence of mental disorders and mental health problems: results from Thai national mental health survey 2013]. นนทบุรี: สำนักบริหารระบบบริการสุขภาพจิต กรมสุขภาพจิต; 2559.

Teter CJ, Kando JC, Wells BG. Major depressive disorder. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, et al, editors. Pharmacotherapy: a pathophysiologic approach. 8th ed. New York: McGraw-Hill; 2011. p. 1173-239.

Fortney JC, Pyne JM, Edlund MJ, Stecker T, Mittal D, Robinson DE, et al. Reasons for antidepressant nonadherence among veterans treated in primary care clinics. J Clin Psychiatry. 2011;72(6):827-34. doi:10.4088/JCP.09m05528blu.

Zolnoori M, Fung KW, Fontelo P, Kharrazi H, Faiola A, Wu YSS, et al. Identifying the underlying factors associated with patients’ attitudes toward antidepressants: qualitative and quantitative analysis of patient drug reviews. JMIR Ment Health. 2018;5(4):e10726. doi:10.2196/10726.

Eveleigh R, Speckens A, van Weel C, Voshaar RO, Lucassen P. Patients’ attitudes to discontinuing not-indicated long-term antidepressant use: barriers and facilitators. Ther Adv Psychopharmacol. 2019;9:1-9. doi:10.1177/2045125319872344.

Maund E, Dewar-Haggart R, Williams S, Bowers H, Geraghty AWA, Leydon G, et al. Barriers and facilitators to discontinuing antidepressant use: A systematic review and thematic synthesis. J Affect Disord. 2019;245:38–62. doi:10.1016/j.jad.2018.10.107.

Montejo AL, Montejo L, Navarro-Cremades F. Sexual side-effects of antidepressant and antipsychotic drugs. Curr Opin Psychiatry. 2015;28(6):418–23. doi:10.1097/YCO.0000000000000198.

Sakthong P, Sonsa‑ardjit N, Sukarnjanaset P, Munpan W, Sangthonganotai T. Development and psychometrics of a short‑form pharmaceutical care‑specific measure for quality of life. Int J Clin Pharm. 2018;40(3):642-9. doi:10.1007/s11096-018-0638-4.

Sakthong P, Suksanga P, Sakulbumrungsil R, Winit-Watjana W. Development of patient-reported outcomes measure of pharmaceutical therapy for quality of life (PROMPT-QoL): a novel instrument for medication management. Res Soc Admin Pharm. 2015;11(3):315-38. doi:10.1016/j.sapharm.2014.10.002.

Cipolle RJ, Strand LM, Morley PC. Pharmaceutical care practice: the clinician’s guide. 2nd ed. New York: McGraw-Hill; 2004.

Sakthong P, Chinthammit C, Sukarnjanaset P, Sonsa-ardjit N, Munpan W. Psychometric properties of the patient-reported outcomes measure of pharmaceutical therapy for quality of life (PR.OMPT-QoL). Value Health Reg Issues. 2017;12:41-9. doi:10.1016/j.vhri.2017.02.003.

Nunnally JC, editors. Psychometric Theory. 2nd ed. New York: McGraw-Hill; 1978.

Neter J, Kutner MH, Nachtsheim CJ, Wasserman W. Applied Linear Statistical Models. 4th ed. New York: McGrow-Hill; 1996.

Yen CF, Chen CC, Lee Y, Tang TC, Ko CH, Yen JY. Association between quality of life and self-stigma, insight, and adverse effects of medication in patients with depressive disorders. Depress Anxiety. 2009;26(11):1033–9. doi:10.1002/da.20413.

Downloads

Published

2021-09-10

How to Cite

1.
Sakthong P, Ralukruedej R. Pharmaceutical therapy-related quality of life in Thai depressive outpatients. J Ment Health Thai [internet]. 2021 Sep. 10 [cited 2026 Jan. 2];29(3):239-48. available from: https://he01.tci-thaijo.org/index.php/jmht/article/view/247579